Galimedix Advances Alzheimer's Research with Successful Phase 1 Completion

Galimedix Therapeutics, a clinical-stage biotechnology firm, announced the completion of its Phase 1 trial for GAL-101, an oral small molecule aimed at misfolded amyloid beta monomers linked to Alzheimer's. This trial, involving over 100 healthy volunteers, demonstrated that GAL-101 is well tolerated with a favorable safety profile. Importantly, the molecule crosses the blood-brain barrier, supporting further development.

The company plans a Phase 2 trial for Alzheimer's, focusing on this area due to limited treatment options currently available. Fundraising efforts are underway to support this next step. Additionally, Galimedix is conducting a Phase 2 trial with GAL-101 eyedrops for dry age-related macular degeneration (dAMD), with ongoing recruitment.

Galimedix seeks to connect with potential investors and partners at upcoming conferences, aiming to discuss investment opportunities and available data.